肝动脉灌注化疗联合免疫靶向治疗晚期肝细胞癌的临床疗效

Clinical efficacy of hepatic artery infusion chemotherapy combined with immunotherapy plus target therapy in the treatment of advanced hepatocellular carcinoma

肝癌是全世界常见的恶性肿瘤,其中我国肝癌每年新发病例数占全世界的一半以上。发病率高、病死率高、治疗手段有限是我国肝癌防治面临的主要挑战。免疫治疗给晚期肝癌病人带来全新的治疗选择和延长生存时间的希望。2020年5月《新英格兰医学杂志》公布的IMbrave150研究结果显示:病人中位生存时间为19.2个月,我国亚群病人中位生存时间长达24.0个月,免疫治疗在延长病人生存时间及控制肿瘤方面疗效显著。介入治疗在肝癌治疗中占重要地位,目前,越来越多的临床研究采用系统治疗联合介入治疗,两者具有协同增效作用,可取得良好临床效果。笔者报道1例晚期肝细胞癌病人应用介入联合阿替利珠单克隆抗体+贝伐珠单克隆抗体治疗的临床经验,其研究结果显示:病人短期内控制肿瘤,取得良好的临床疗效。

Hepatocellular carcinoma(HCC)is one of the most common malignant tumors in the world,and the new cases of HCC in China account for more than half of the global cases every year.High incidence mortality and limited treatment methods are the main challen-ges for HCC prevention and treatment in China.Immunotherapy has brought new treatment options and hope of prolonging the survival to patients with advanced HCC.Data from the IMbrave 150 study published in the New England Journal of Medicine in May 2020 showed that the median overall survival of all patients was 19.2 months,and the median overall survival of the Chinese subgroup was 24.0 months,which suggested significant efficacy in prolongating patient survival and controlling tumor.Interventional therapy has been playing an important role in the treatment of HCC,and more and more clinical studies have adopted systematic therapy combined with interventional therapy.Interventional therapy and systematic therapy have synergistic efficacy which lead to significant clinical efficacy.The authors introduce the diagnosis and treatment of an advanced HCC patient undergoing interventional therapy combined with bevacizumab plus attilizumab treatment,which lead to significant clinical efficacy of tumor controlling.